CO2022000254A2 - Composición farmacéutica para suministro nasal - Google Patents

Composición farmacéutica para suministro nasal

Info

Publication number
CO2022000254A2
CO2022000254A2 CONC2022/0000254A CO2022000254A CO2022000254A2 CO 2022000254 A2 CO2022000254 A2 CO 2022000254A2 CO 2022000254 A CO2022000254 A CO 2022000254A CO 2022000254 A2 CO2022000254 A2 CO 2022000254A2
Authority
CO
Colombia
Prior art keywords
compositions
pharmaceutical composition
pharmaceutically acceptable
applicators
opioid antagonist
Prior art date
Application number
CONC2022/0000254A
Other languages
English (en)
Spanish (es)
Inventor
Jonas Sävmarker
Robert Rönn
Andreas Fischer
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of CO2022000254A2 publication Critical patent/CO2022000254A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2022/0000254A 2019-07-09 2022-01-14 Composición farmacéutica para suministro nasal CO2022000254A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/506,023 US10653690B1 (en) 2019-07-09 2019-07-09 Pharmaceutical composition for nasal delivery
PCT/GB2020/051207 WO2021005325A1 (en) 2019-07-09 2020-05-18 Pharmaceutical composition for nasal delivery

Publications (1)

Publication Number Publication Date
CO2022000254A2 true CO2022000254A2 (es) 2022-04-29

Family

ID=70736393

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000254A CO2022000254A2 (es) 2019-07-09 2022-01-14 Composición farmacéutica para suministro nasal

Country Status (15)

Country Link
US (1) US10653690B1 (cg-RX-API-DMAC10.html)
EP (1) EP3996687A1 (cg-RX-API-DMAC10.html)
JP (1) JP7753183B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220034153A (cg-RX-API-DMAC10.html)
CN (1) CN114096249B (cg-RX-API-DMAC10.html)
AU (1) AU2020311020B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022000260A2 (cg-RX-API-DMAC10.html)
CA (1) CA3145965A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000033A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022000254A2 (cg-RX-API-DMAC10.html)
IL (1) IL289513B1 (cg-RX-API-DMAC10.html)
MX (1) MX429050B (cg-RX-API-DMAC10.html)
PE (1) PE20220581A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022550009A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021005325A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134943A1 (en) 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
US10729687B1 (en) * 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
FR3098407B1 (fr) * 2019-07-10 2024-12-13 Aptar France Sas Dispositif de distribution nasale de poudre
WO2021102328A1 (en) * 2019-11-21 2021-05-27 Torralva Medical Therapeutics Llc Prophylaxis and reversal of stimulant and opioid/opiate overdose and/or toxic exposure
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
EP4284506A4 (en) * 2021-02-01 2024-12-25 Clear Scientific, Inc. SEQUESTRATION COMPOUNDS FOR THE TREATMENT OF SUBSTANCE USE DISORDER AND USES THEREOF
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12661315B2 (en) 2021-06-10 2026-06-23 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
GB202117007D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
GB202117015D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
IL313015A (en) 2021-11-25 2024-07-01 Orexo Ab A pharmaceutical preparation that includes biopharmaceutical drug compounds
GB202117005D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
US12005185B2 (en) 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
KR20260016535A (ko) 2023-05-31 2026-02-03 오렉쏘 에이비 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물
GB202308123D0 (en) 2023-05-31 2023-07-12 Orexo Ab New copmosition
CN119326740A (zh) * 2024-12-18 2025-01-21 纳索菲德(上海)制药技术有限公司 一种治疗生物节律失调的鼻脑递释制剂

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
DE69425948T2 (de) 1993-12-06 2001-02-22 Takeda Chemical Industries, Ltd. Zusammensetzung mit verbesserter Wasserlöslichkeit, enthaltend eine Wasserunlösliche oder an Wasser schwerunlösliche Verbindung
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
DE69913113T2 (de) 1998-03-10 2004-08-26 Valois S.A.S. Behälter, verfahren zur befüllung dieses behälter und abgabevorrichtung für das im behälter enthaltene pulver
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
AU2003296954A1 (en) 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
KR20120066688A (ko) * 2003-02-24 2012-06-22 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
CA2540204A1 (en) 2003-10-09 2005-04-21 Bioactis Limited Device to deliver powdery medicine into nasal cavity
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1305474C (zh) * 2004-10-13 2007-03-21 北京国药龙立生物医药新技术有限公司 盐酸纳美芬鼻腔给药制剂
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
CA2601969A1 (en) 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
WO2008033023A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
JP5437232B2 (ja) 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
CN102068697B (zh) * 2010-12-30 2013-10-16 宜昌人福药业有限责任公司 含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
HRP20180233T1 (hr) * 2011-05-13 2018-06-01 Euro-Celtique S.A. Intranazalni farmaceutski oblici doziranja koji sadrže nalokson
CN104470569B (zh) 2012-06-28 2018-04-27 美国政府(由卫生和人类服务部的部长所代表) 用于疫苗和其它治疗试剂的鼻干粉递送系统
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016016431A1 (en) 2014-08-01 2016-02-04 Krka, D.D., Novo Mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
JP6719460B2 (ja) 2014-11-14 2020-07-08 アゾルテック・ソチエタ・ア・レスポンサビリタ・リミタータＡＳＯＬＴＥＣＨ Ｓ．ｒ．ｌ． Ｃｏｑ１０に基にした組成物
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) * 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
UA121874C2 (uk) 2015-02-17 2020-08-10 Елі Ліллі Енд Компані Порошкова назальна композиція для лікування гіпоглікемії
CA2981991A1 (en) 2015-04-08 2016-10-13 Chang-Chun LING Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
EP3400066B1 (en) * 2016-01-08 2021-07-28 Ohio State Innovation Foundation Treatments and prevention of opioid neonatal abstinence syndrome
WO2017158439A1 (en) 2016-03-16 2017-09-21 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
NZ750067A (en) * 2016-06-24 2025-11-28 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of alcohol use disorder
MX2019001467A (es) * 2016-08-03 2019-10-02 Remd Biotherapeutics Inc Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
EP3518894A1 (en) 2016-09-28 2019-08-07 Chrono Therapeutics Inc. Transdermal drug delivery device for delivering opioids
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
CA3043028A1 (en) 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
WO2018093666A1 (en) 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
CN106361700A (zh) * 2016-11-25 2017-02-01 威海恒基伟业信息科技发展有限公司 盐酸纳美芬鼻腔给药制剂
US10394770B2 (en) 2016-12-30 2019-08-27 General Electric Company Methods and systems for implementing a data reconciliation framework
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
CN110996912A (zh) 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
CN109953952A (zh) * 2017-12-25 2019-07-02 王旭宁 盐酸纳美芬鼻腔给药制剂

Also Published As

Publication number Publication date
US10653690B1 (en) 2020-05-19
EP3996687A1 (en) 2022-05-18
CA3145965A1 (en) 2021-01-14
IL289513A (en) 2022-03-01
JP2022540227A (ja) 2022-09-14
JP7753183B2 (ja) 2025-10-14
PH12022550009A1 (en) 2022-11-21
CN114096249A (zh) 2022-02-25
WO2021005325A1 (en) 2021-01-14
AU2020311020B2 (en) 2026-03-05
AU2020311020A1 (en) 2022-03-03
KR20220034153A (ko) 2022-03-17
MX429050B (es) 2025-11-13
CL2022000033A1 (es) 2022-08-19
PE20220581A1 (es) 2022-04-20
CN114096249B (zh) 2025-02-11
MX2022000368A (es) 2022-02-03
IL289513B1 (en) 2026-06-01
BR112022000260A2 (pt) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2022000033A1 (es) Composición farmacéutica para suministro nasal
CL2022002979A1 (es) Nueva composición farmacéutica para administración de fármacos
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
MX378315B (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos
PE20140604A1 (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
PE20160665A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
AR127780A1 (es) Nueva composición farmacéutica que comprende adrenalina
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
ECSP17085669A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
MX2016000964A (es) Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
BR112015020707A2 (pt) formulações transdermicas
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
MX2019004941A (es) Formulacion liposomal.
MX375427B (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.